|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
As B35 is the most prevalent HLA-B in Mexico, we investigated HIV disease outcome in relation to HLA expression in a large cohort (n=976) of Mexicans.
|
24853499 |
2014 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
Carriage of alleles encoding certain inhibitory natural killer (NK) cell receptor/HLA ligand KIR3DL1/HLA-B combinations is associated with protection from HIV infection and slow time to AIDS, implicating NK cells in HIV control.
|
27499379 |
2017 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
CTD_human |
The various epistatic effects observed here for common, distinct KIR3DL1 and HLA-B Bw4 combinations are unprecedented with regard to any pair of genetic loci in human disease, and indicate that NK cells may have a critical role in the natural history of HIV infection.
|
17496894 |
2007 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
Kaplan Meier analysis revealed significantly increased mortality in HLA-B*57-positive patients with HIV-infection (p=0.032) and HIV/HCV-co-infection (p=0.004), which was apparently linked to non-viral infections.
|
26241854 |
2015 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.
|
28369189 |
2017 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
HLA-B*5703 seems to be a protective allele against the progression of HIV infection but could influence the increased incidence of SpA observed in this population.
|
15641063 |
2005 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
HIV subtype influences HLA-B*07:02-associated HIV disease outcome.
|
24010680 |
2014 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
Hence, aim of this study was to document association of HLA-B with HIV infection in DCs living in Mumbai, India.
|
24029662 |
2014 |
|
HIV Infections
|
0.500 |
Biomarker
|
group |
BEFREE |
In two HIV C clade-infected populations in South Africa and Zambia, we sought to elucidate the role of HLA-B*5703 in HIV disease outcome.
|
19307327 |
2009 |
|
HIV Infections
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In early HIV infection, host expression of the protective HLA-B*81 allele was associated with lower RC (<i>P</i> = 0.05), as was expression of HLA-B*07 (<i>P</i> = 0.02), suggesting early immune-driven attenuation of RT-integrase by these alleles.
|
29997209 |
2018 |
|
HIV Infections
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In addition, these studies identify a factor contributing to different HIV disease outcomes in individuals expressing HLA-B*5703.
|
21498667 |
2011 |
|
HIV Infections
|
0.500 |
AlteredExpression
|
group |
BEFREE |
A similar scenario is observed in humans where the expression of HLA-B*27 or HLA-B*57 has been linked to slow or no progression to AIDS after HIV infection.
|
26811146 |
2016 |